Severe acute respiratory syndrome coronavirus 2

Anixa Biosciences to Present at Biotech Showcase 2023

Retrieved on: 
Monday, December 19, 2022
Cleveland Clinic, Breast cancer, H. Lee Moffitt Cancer Center & Research Institute, Protein, Sumathi Best Television Current Reporting Award, Annual report, SAN, Biotechnology, Hilton San Francisco Union Square, Ovarian cancer, Cancer, TNBC, Infection, Risk, Disease, Severe acute respiratory syndrome coronavirus 2, COVID-19, Therapy, Mpro, Pharmaceutical industry

SAN JOSE, Calif., Dec. 19, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it will present at the Biotech Showcase 2023 conference being held in-person on January 9-11, 2023, at the Hilton San Francisco Union Square in San Francisco, California, and virtually on January 18-19, 2023.

Key Points: 
  • SAN JOSE, Calif., Dec. 19, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it will present at the Biotech Showcase 2023 conference being held in-person on January 9-11, 2023, at the Hilton San Francisco Union Square in San Francisco, California, and virtually on January 18-19, 2023.
  • Biotech Showcase is one of the industry's largest annual healthcare investor and partnering conferences, bringing together biopharmaceutical and life sciences company executives, investors, sector analysts, bankers, and industry stakeholders.
  • More than 350 presentations from mid-, small- and micro-cap public and private companies are expected to present at the event.
  • Qualified investors and buy- and sell-side analysts are invited to request a complimentary registration to attend Biotech Showcase.

Ascletis Announces Notice of Issuance of the U.S. Patent for Oral Viral Polymerase Inhibitor ASC10 and Its Derivatives

Retrieved on: 
Monday, December 19, 2022
RSV, Respiratory syncytial virus, Degenerative disease, Monkeypox virus, Use, Hong Kong Stock Exchange, Primary biliary cholangitis, Patent, NASH, HBV, United States Patent and Trademark Office, NHC, HKEX, Infection, Fatty liver disease, Severe acute respiratory syndrome coronavirus 2, PBC, Acne, COVID-19, Patient, Vaccine, Pharmaceutical industry

HANGZHOU and SHAOXING, China, Dec. 19, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that it has received the Notice of Issuance from the United States Patent and Trademark Office (USPTO) for the patent application of oral viral polymerase inhibitor ASC10 and its derivatives, and their uses to treat multiple virus infections including SARS-CoV-2, monkeypox virus and respiratory syncytial virus (RSV). The issue date of the patent will be January 3, 2023 by the USPTO and the patent title is Nucleoside Derivatives and Methods of Use Thereof (U.S. patent number: 11,541,071).

Key Points: 
  • The issuance of the U.S. patent further strengthens Ascletis' patent portfolio in viral diseases
    HANGZHOU and SHAOXING, China, Dec. 19, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that it has received the Notice of Issuance from the United States Patent and Trademark Office (USPTO) for the patent application of oral viral polymerase inhibitor ASC10 and its derivatives, and their uses to treat multiple virus infections including SARS-CoV-2, monkeypox virus and respiratory syncytial virus (RSV).
  • The issue date of the patent will be January 3, 2023 by the USPTO and the patent title is Nucleoside Derivatives and Methods of Use Thereof (U.S. patent number: 11,541,071).
  • With this issue notification, Ascletis has become the first Chinese biotech company which has been granted a patent by the USPTO for its in-house developed oral viral polymerase inhibitor and its derivatives.
  • "The issuance of the U.S. patent for our oral viral polymerase inhibitor ASC10 and its derivatives, and their uses further strengthens our patent portfolio in viral diseases.

Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5

Retrieved on: 
Sunday, December 18, 2022
Roche, Virology, Patient, AMD, Inflammation, Membrane protein, Antibody, Omicron, Probability, IPF, Doctor of Philosophy, Pioglitazone, Vaccine, COVID-19, Infection, Research, MAPK, Severe acute respiratory syndrome coronavirus 2, KNRS, Therapy, Pharmaceutical industry, Muthiri kinaru

Basel, Switzerland, 6 December 2022 -- Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, announced new preclinical data showing KIN001’s strong antiviral efficacy against the SARS-CoV-2 Omicron subvariants BA.2 and BA.5.

Key Points: 

    Dyadic's DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal

    Retrieved on: 
    Wednesday, December 14, 2022
    Protein, Clinical trial, Animal, Health, Antibody, VTT Technical Research Centre of Finland, Safety, RBD, ACE2, Vaccine, Human, Drug Quality and Security Act, Israel Institute for Biological Research, Risk, Biology, Toxicology, Organization, Research, Food, Severe acute respiratory syndrome coronavirus 2, Antigen, China Biologic Products, COVID-19, Fine chemical, Dyadic

    JUPITER, Fla., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), announced today that its study titled "Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel®85 Protects K18-hACE2 Mice against Lethal Virus Challenge" has been published in VACCINES, a leading peer-reviewed scientific journal as part of the Special Issue “Vaccine Candidate against SARS-CoV-2”.

    Key Points: 

      IMUNON Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)

      Retrieved on: 
      Wednesday, December 14, 2022
      Immunotherapy, Organic acid, Employment, Failure, Cyprus Securities and Exchange Commission, Security (finance), Phase II, Interleukin, DNA, Cancer, News, Patient, Infection, Research, Financial compensation, Severe acute respiratory syndrome coronavirus 2, Risk, Pharmaceutical industry

      The equity awards were approved in accordance with Nasdaq Listing Rule 5635 (c)(4).

      Key Points: 
      • The equity awards were approved in accordance with Nasdaq Listing Rule 5635 (c)(4).
      • The Inducement Option Grants have an exercise price per share equal to $1.40 which is equal to the closing price of IMUNON's common stock as reported by Nasdaq on December 13, 2022.
      • IMUNON will continue to leverage these modalities and to advance the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions.
      • IMUNON assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

      PaxMedica, Inc. Launches Updated Corporate Website at PaxMedica.com

      Retrieved on: 
      Wednesday, December 14, 2022
      ASD, Disorder, Incidence, Autism, Process, Autism spectrum, Suramin, Severe acute respiratory syndrome coronavirus 2, COVID-19, Cognitive disorder, Risk management, Pharmaceutical industry

      Tarrytown, NY, Dec. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today announced that the Company has launched a newly updated corporate website at www.paxmedica.com.

      Key Points: 
      • Howard Weisman, Chief Executive Officer of PaxMedica, commented, “Our new website underscores our ongoing commitment to develop therapeutic advancements to treat core symptoms of autism and other potentially related disorders with intractable neurologic symptoms.
      • Key features of the refreshed website include an updated design and a more engaging interface, as well as better segmentation of the key subjects and sections.
      • For more information, please visit: www.paxmedica.com
        This press release contains “forward-looking statements.” Forward-looking statements reflect our current view about future events.
      • most recent quarterly reports and other filings with the U.S. Securities and Exchange Commission.

      Icosavax Reports Positive Durability Data for VLP Vaccine Candidate IVX-121 Against RSV at Six-Month Timepoint

      Retrieved on: 
      Tuesday, December 13, 2022
      RSV, GMT, Clinical trial, Phase 1, Security (finance), Severe acute respiratory syndrome coronavirus 2, Rolex GMT Master II, NAB, Human, Vaccine, VLP, University of Washington Department of Global Health, Infection, Pneumonia, Research, Virus, Risk, University, WHO, Medical device, Pharmaceutical industry

      SEATTLE, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today provided a six-month immunogenicity update from its Phase 1/1b trial of IVX-121 against Respiratory Syncytial Virus (RSV). These new data demonstrate a sustained neutralizing antibody (nAb) response against RSV, lasting for at least six months after a single administration of IVX-121.

      Key Points: 
      • These new data demonstrate a sustained neutralizing antibody (nAb) response against RSV, lasting for at least six months after a single administration of IVX-121.
      • “We are delighted to share the six-month immunogenicity data from our Phase 1/1b trial of IVX-121.
      • Icosavax plans to provide a 12-month immunogenicity update from an extension of this Phase 1b trial in mid-2023.
      • The company also intends to present additional data from its Phase 1/1b clinical trial of IVX-121 at a future medical meeting.

      Gritstone bio Granted Two New U.S. Patents for Self-amplifying mRNA (samRNA)

      Retrieved on: 
      Tuesday, December 13, 2022
      RNA, EDGE, Nature Biotechnology, Annual report, Epitope, Membrane protein, Security (finance), Immunology, Degenerative disease, Patent, Genome, Vaccine, Infection, RNA transfection, IP, Immune system, 1836 U.S. Patent Office fire, Severe acute respiratory syndrome coronavirus 2, Antigen, CORAL, Therapy, Pharmaceutical industry, Gritstone

      11,510,973 includes claims covering antigen-encoding samRNA vectors and has broad applicability across Gritstone’s candidates in oncology and infectious disease.

      Key Points: 
      • 11,510,973 includes claims covering antigen-encoding samRNA vectors and has broad applicability across Gritstone’s candidates in oncology and infectious disease.
      • Gritstone currently has eight applications granted or allowed in the United States, and approximately 300 patent applications pending in the United States and other jurisdictions.
      • Like traditional mRNA vaccines, samRNA vaccines use the host cell’s transcription system to produce target antigens to stimulate adaptive immunity.
      • Once identified, Gritstone then delivers its novel vaccine candidates (self-amplifying mRNA) to these optimal targets to drive neutralizing antibody and T cell immune response.

      Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection

      Retrieved on: 
      Tuesday, December 13, 2022
      RNA, Hepatitis B, Coronavirus, Patient, Drug discovery, World Health Organization, Clinical trial, Annual report, RNA interference, PD, Hepatitis, Membrane protein, N-Acetylgalactosamine, HBsAg, Hepatocyte, SE, Safety, Non-cirrhotic portal fibrosis, Degenerative disease, Death, NA, HBV, Liver cancer, Hepatitis B virus, Risk, Vaccine, Drug Quality and Security Act, HBeAg, Arbutus, Virology, Immune system, Severe acute respiratory syndrome coronavirus 2, Patent, Antigen, CFBV, Cirrhosis, COVID-19, Therapy, Conditional sentence, Pharmaceutical industry, Peginterferon-alfa

      WARMINSTER, Pa., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced preliminary data from the AB-729 lead-in portion of its Phase 2a clinical trial combining AB-729 with nucleos(t)ide analogue (NA) therapy and Peginterferon alfa-2a (IFN). The data reinforces AB-729’s surface antigen reducing-capacity, while continuing to exhibit a generally safe and well-tolerated profile in patients with chronic Hepatitis B virus (cHBV). Given that only a few patients are in the early weeks of the IFN phase of the clinical trial, the Company intends to provide additional updated data in the first half of next year which will include preliminary results of the IFN portion of the trial.

      Key Points: 
      • The data reinforces AB-729’s surface antigen reducing-capacity, while continuing to exhibit a generally safe and well-tolerated profile in patients with chronic Hepatitis B virus (cHBV).
      • Enrollment is complete in the clinical trial with 43 patients having received at least one dose of AB-729.
      • As the trial progresses, patients will be randomized into various treatment arms which include the combination of AB-729, NA therapy and short courses of IFN for either 12 or 24 weeks.
      • Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV).

      Enzo Biochem Reports First Quarter Fiscal Year 2023 Financial Results and Provides Business Update

      Retrieved on: 
      Monday, December 12, 2022
      Conference, Molecular biology, GMP, Internet, NYSE, Antibody, Genomics, Immunology, Cancer, B cell, Biotechnology, HPV, Power, Acceleration, ENZ, Drug development, Neuroscience, Public expenditure, Toxicology, Growth, Investment, Severe acute respiratory syndrome coronavirus 2, General counsel, Precision medicine, Conference call, Patient, GAAP, FX, COVID, Pharmaceutical industry, Fine chemical, Mobile phone, Medical imaging, Video game, Renewable energy

      FARMINGDALE, N.Y., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today reported operating results for the first quarter ended October 31, 2022 of Fiscal Year 2023 (Q1 FY23) and provided a business update on recent corporate and operational developments.

      Key Points: